Krishnan Anbarasu

Dr. Krishnan Anbarasu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
KGKadiyala Gopi
Kadiyala Gopi
KAKrishnan Anbarasu
Krishnan Anbarasu
KRKadali Renu
Kadali Renu
SJS. Jayanthi
S. Jayanthi
BVB.S. Vishwanath
B.S. Vishwanath
GJGurunathan Jayaraman
Gurunathan Jayaraman

13 March 2013 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
NCNAVEED ANJUM CHIKAN
NAVEED ANJUM CHIKAN
VBV. Bhavaniprasad
V. Bhavaniprasad
KAKrishnan Anbarasu
Krishnan Anbarasu
NSNadeem Shabir
Nadeem Shabir
TPTrupti Patel
Trupti Patel

8 April 2016 in Journal of Receptors and Signal Transduction
Verified
Journal Article
Closed access
PDF file
KAKrishnan Anbarasu
Krishnan Anbarasu
SJS. Jayanthi
S. Jayanthi
Estrogen receptor-α (ERα) is expressed more in patients with breast cancer and its level correlated with endocrine resistance. LMTK3 is reported as breast cancer target with regulation of estrogen receptor-α (ERα) through phosphorylation. In this computational study, structure-based inhibitor screening was performed on human LMTK3 using ZINC database. ATP-binding cavity with critical residues involved in the LMTK3 phosphorylation was used as target site for the screening. From the large ligand library, the best compounds were screen with three-phase virtual screening methods in Dockblaster, AutoDock Vina and AutoDock, respectively. The evaluation of ligands was carried out by binding energy and weak interactions, such as hydrogen bond interactions and hydrophobic contacts, in the target site that favors LMTK3 inhibition. Top compounds were found to be more effective in druglikeness activity by ADME prediction. The stability and binding affinity of ligand complexes were optimized by trajectory analysis such as RMSD, Rg, SASA and interhydrogen bonds from molecular dynamics simulations. The behavior of protein motion after ligand binding was illustrated by eigenvectors from principal component analysis (PCA). In addition, binding free energy of the LMTK3–ligand complexes were calculated by MM/PBSA methods and results supported the strong binding in dynamic system. Thus, the computational studies illustrated the structural insights on LMTK3 inhibition mechanism by ligands ZINC04670539, ZINC05607079 and ZINC04344028, also proposed as potent lead candidates. Our findings step towards developing novel LMTK3 inhibitors and identified lead candidates can be future breast cancer drugs with further experimental studies.

5 March 2014 in Molecular BioSystems
Verified
Journal Article
Closed access
PDF file
KAKrishnan Anbarasu
Krishnan Anbarasu
SJS. Jayanthi
S. Jayanthi
Estrogen positive breast cancer is a dreadful disease in women worldwide. The human estrogen receptor-α (ERα) pathway plays a critical role in estrogenic signaling and targeting ERα in breast cancer treatment. The key role of Lemur tyrosine kinase-3 (LMTK3) in regulation of ERα has been identified and it is found to be a novel therapeutic target for breast cancer. With lack of structural studies on LMTK3, the breast cancer therapeutics research remains elusive. In this computational study, we performed structural studies on LMTK3 by structural modeling and molecular dynamics (MD) simulations of the apo state and the ATP bound state. The structure of the LMTK3 domain was developed by using I-TASSER server and validated by quality index and Ramachandran plot. MD simulation analysis explained the structural behavior of the LMTK3 domain in the dynamic system and the apo state showed defined protein folding with stable conformation. The mechanism of ATP binding was studied using molecular docking, resulting in the identification of critical residues and the ATP binding cavity. Furthermore, MD simulation of the LMTK3–ATP complex was performed and the trajectory analyses confirmed the stability and effective binding of ATP in the dynamic system. Overall, our computational reports provide more information on the structure–function relationship of LMTK3 with ATP. The critical residues Tyr185 and Asp284 found in the ATP binding cavity may be useful in designing potential inhibitors on human LMTK3.

Verified
Journal Article
Open access
PDF file
SRSuresh Raghavi
Suresh Raghavi
BDBalakrishnan Deva Darshini
Balakrishnan Deva Darshini
Konda Mani SaravananKonda Mani Saravanan
Konda Mani Saravanan
KAKrishnan Anbarasu
Krishnan Anbarasu
The bioactive compounds that are produced by leeches combine traditional and modern treatment since the saliva of the animal contains proteins and peptides with anticoagulant, anti-inflammatory, antimicrobial, antioxidant, and regenerative properties. In this review, their biochemical profile, mechanisms and clinical uses are considered with a special focus on the fact that they are utilized to combine traditional practices with the modern developments in biomedical approaches. Proteomic and transcriptomic research has recently found more than 100 bioactive molecules, such as hirudin, calin, eglins, bdellins and destabilase, which are related to the blood-feeding process and therapeutic processes. These compounds control blood clotting, control inflammatory mediators, block microbes and enhance wound healing and the development of new blood vessels. In clinical practice, leech therapy is common in the reconstruction and microsurgical practice to reduce venous congestion and enhance graft success. They are also shown to be useful in wound healing, cardiovascular health, musculoskeletal conditions and regenerative medicine, as well as emerging drug delivery systems of recombinant proteins and nanocarriers. Some of the challenges involve biological variation, infection or bleeding risks and stringent regulations on purity and standardization. Biotechnology has improved through other developments such as recombinant protein production, high-throughput omics, and nanotechnology, which will help resolve these problems, making them safe and scalable for clinical use. Altogether, leech bioactives are the prime examples of the sophisticated pharmacology of nature, which have the potential of being used as therapeutic agents in the future. The recent approach and incorporation in personalized medicine and bioengineering models reflect the leech’s capacity to address complicated illness and unmet healthcare requirements to reassert its significance in preventive medicine and recent biomedicine.

9 July 2025 in Environmental Monitoring and Assessment
Verified
Journal Article
Closed access
PDF file
KAKrishnan Anbarasu
Krishnan Anbarasu
Yuvarajan DevarajanYuvarajan Devarajan
Yuvarajan Devarajan
BNBeemkumar Nagappan
Beemkumar Nagappan
DKDhruv Kumar
Dhruv Kumar
VUVijay J. Upadhye
Vijay J. Upadhye